Review article: the treatment of functional abdominal bloating and distension

@article{Schmulson2011ReviewAT,
  title={Review article: the treatment of functional abdominal bloating and distension},
  author={M W Schmulson and L. Chang},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2011},
  volume={33}
}
Aliment Pharmacol Ther 2011; 33: 1071–1086 
Diet Therapy in the Context of Chronic Pelvic Pain
TLDR
The synergistic relationship between food and well-being is beyond doubt and there is now abundant evidence that comestibles enhance health through complex biological mechanisms. Expand
Bloating and Abdominal Distension: Clinical Approach and Management
TLDR
The proposed underlying mechanisms include visceral hypersensitivity, behavioral induced abnormal abdominal wall-phrenic reflexes, the effect of poorly absorbed fermentable carbohydrates, and microbiome alterations. Expand
Abdominal Bloating: Pathophysiology and Treatment
TLDR
Medical treatment with some prokinetics, rifaximin, lubiprostone and linaclotide could be considered in the treatment of bloating, and dietary intervention is important in relieving symptom in patients with bloating. Expand
Treatment of bloating and distension ‐ role of probiotics
TLDR
Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial. Expand
Functional Abdominal Bloating with Distention
TLDR
No treatment is of unequivocal benefit but a low FODMAPs diet, probiotics and the non-absorbable antibiotic rifaximin offer some hope. Expand
Treatment of bloating and distension – role of probiotics: authors’ reply
TLDR
Using objective and validated parameters, this study believes that it has addressed some of the shortcomings of therapeutic intervention studies in IBS by addressing heterogeneity of the study population, inconsistent use of defined criteria and the subjectivity of outcome measures. Expand
Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation‐predominant irritable bowel syndrome and functional constipation
  • L. Neri, P. Iovino
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2016
TLDR
The association of bloating with patient‐reported outcomes was evaluated and the relationship with patients' well‐being and treatment satisfaction independent of other abdominal symptoms is uncharacterized. Expand
Bloating and abdominal distention: Just gas?: A look in the direction of physiology
TLDR
Some aspects of bloating, abdominal distention and similar symptoms related to intestinal gas and its transit, visceral hypersensitivity, viscerosomatic response and to the intestinal microbiota are discussed. Expand
Conséquences d’un stress chronique sur la barrière de mucus intestinal chez le rat : effet du probiotique Lactobacillus farciminis
TLDR
A large body of literature incriminating mucus alterations in the pathogenesis of Intestinal Bowel Diseases suggests that structural and physical changes in the mucus layer remain poor and need to be investigated further. Expand
Bloating: Avicenna's Perspective and Modern Medicine.
TLDR
Modern scientific data support all bloating causes that have been mentioned in the canon, according to Avicenna, which include diet causes, inappropriate lifestyle, gastrointestinal, and miscellaneous reasons. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 178 REFERENCES
Efficacy of cisapride therapy in functional dyspepsia
TLDR
The objective is to assess the efficacy of cisapride therapy in relieving symptoms of functional dyspepsia and to establish a protocol for evaluating its use in clinical practice. Expand
Non‐absorbable antibiotics for managing intestinal gas production and gas‐related symptoms
Simethicone, activated charcoal and antimicrobial drugs have been used to treat gas‐related symptoms with conflicting results.
Double‐blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome
TLDR
The aim is to study the effect of prokinetic treatment with cisapride in patients with constipation‐predominant irritable bowel syndrome with the aim of determining its role in relieving symptoms. Expand
A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention
TLDR
The presence of probiotics inIrritable bowel syndrome is a gastrointestinal disorder of unknown aetiology and the effect of Probiotics in this syndrome remains unclear. Expand
Efficacy of tegaserod for functional constipation in Chinese subjects: a randomized double‐blind controlled trial in a single centre
TLDR
Tegaserod has been shown to be effective in chronic constipation in Western population and should be considered as a first line treatment for diarrhea in adults. Expand
Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies
TLDR
This clinical trial aimed at determining the causative mechanism behind irritable bowel syndrome with constipation (IBS‐C) and its prognosis was successful in patients with symptomatic IBS-C. Expand
The effect of fluoxetine in patients with pain and constipation‐predominant irritable bowel syndrome: a double‐blind randomized‐controlled study
TLDR
This data indicates that continuation of treatment with selective serotonin reuptake inhibitors for irritable bowel syndrome should be continued for at least two years after initial treatment with these inhibitors. Expand
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating
  • H. J. Kim, M. V. Vazquez Roque, +5 authors A. Zinsmeister
  • Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2005
Abstract  Aim:  To evaluate the effects of a combination probiotic on symptoms and colonic transit in patients with irritable bowel syndrome (IBS) and significant bloating.
Otilonium bromide in irritable bowel syndrome: a double‐blind, placebo‐controlled, 15‐week study
To evaluate the efficacy of otilonium bromide, a spasmolytic agent, in the treatment of irritable bowel syndrome using modern and validated diagnostic criteria.
...
1
2
3
4
5
...